Trial · NCT06823843
The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow
NCT06823843, Phase 4, Completed, VZW Cardiovascular Research Center Aalst
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow. Trials, record NCT06823843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06823843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow
- NCT number
- NCT06823843
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 40 participants, actual
- Lead sponsor
- VZW Cardiovascular Research Center Aalst
- Conditions
- Coronary Arterial Disease (CAD), Angina (Stable)
- Interventions
- Glycerin trinitrate (GTN), Saline (NaCl 0,9 %) (placebo)
- First posted
- 2025-02-12
- Last updated
- 2025-03-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the absolute coronary flow 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Absolute coronary flow will be measured using continuous intracoronary thermodilution |
| Secondary | Change from baseline in the absolute microvascular resistance 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Absolute microvascular resistance will be calculated using absolute coronary flow and distal coronary pressure |
| Secondary | Change from baseline in the absolute epicardial resistance 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Absolute epicardial resistance will be calculated using absolute coronary flow, aortic pressure and distal coronary pressure |
| Secondary | Change from baseline in aortic pressure 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Aortic pressure will be measured using the coronary guiding catheter |
| Secondary | Change from baseline in distal coronary pressure 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Distal coronary pressure will be measured using a standard coronary pressure wire |
| Secondary | Change from baseline in left ventricular end-diastolic pressure 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | LVEDP will be measured using a pigtail catheter at baseline, and at the end of the protocol |
| Secondary | Change from baseline in left ventricular work 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Left ventricular work will be estimated using the systolic pressure-time index (SPTI) derived from the aortic pressure curve. |
| Secondary | Change from baseline in myocardial perfusion 10 minutes after administration of the intervention | 10 minutes from the administration of the sublingual intervention | Myocardial perfusion will be estimated using the Buckberg Index. It will be calculated by dividing the diastolic pressure-time index (i.e. time of coronary perfusion) by the systolic pressure-time index (i.e. time of myocardial oxygen demand). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06823843
GET https://conductscience.org/api/trials/v1/NCT06823843/registered